Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГУ Республиканский научно-практический центр психического здоровья. 220053, Беларусь, Минск, Долгиновский тракт, д. 152; 2УО Белорусский государственный медицинский университет. 220116, Беларусь, Минск, пр. Дзержинского, д. 83
Список исп. литературыСкрыть список 1. Schneider K. Klinische Psychopathologie. Stuggart: Thieme, 1971. 2. Kretschemer E. Rjrperbau und charakter: Untersuchungen zum konstituons – problem und zur lehre von den temperamenten. Berlin: Springer-Verlag, 1994. 3. Stransky E. Lehrbuch der allgemeinen und speciellen Psychiatrie. Berlin: Bergmann, 1994. 4. Kraepelin E. Dementia Praecox and Paraphrenia. New York: Robert D.Krieger Publishing, 1919. 5. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press, 1950. 6. Minkowski E. La schizophrenie. Paris: Dosclee de Brourver, 1927. 7. Liddle PF. The symptoms of chronic schizophrenia. A reexamination of the positive-negative dichotomy. Br J Psychiatr 1987; 151: 145–51. 8. Andreasen NC et al. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52: 341–51. 9. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 1987; 17: 49–57. 10. Andreasen N et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr 2005; 162: 441–9. 11. Johnstone EC, Frith CD. Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients. Psychol Med 1996; 26: 669–79. 12. Grube BS, Bilder RM, Goldman RS. Meta-analysis of symptom factors in schizophrenia. Schizophr Res 1998; 31: 113–20. 13. Smith DA, Mar CM, Turoff BK. The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis. Schizophr Res 1998; 31: 57–70. 14. Ventura J et al. Disorganization and reality distortion in schizophrenia: A meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res 2010; 121: 1–14. 15. Siguado M et al. Quality of life in stable schizophrenia: The relative contributions of disorganization and cognitive dysfunction. Schizophr Res 2014; 153: 196–203. 16. Ventura J et al. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009; 113: 189–99. 17. Нестерович А.Н. Феномен дезорганизации при шизофрении: современные представления и биологические корреляты. Обзор литературы. Мед. панорама. 2015; 5: 37–43. / Nesterovich A.N. Fenomen dezorganizatsii pri shizofrenii: sovremennye predstavleniia i biologicheskie korreliaty. Obzor literatury. Med. panorama. 2015; 5: 37–43. [in Russian] 18. Jacques PF et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93 (1): 7–9. 19. Lipton S et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997; 94: 5923–8. 20. Sharma RP et al. CpG Methylation in Neurons: Message, Memory, or Mask? Neuropsychopharmacology 2010; 35: 2009–20. 21. Ono T et al. Biological significance of DNA methylation in the ageing process. Age Ageing 1993; 22: S34–S43. 22. Lim C et al. Psychosocial Factors in the Neurobiology of Schizophrenia: A Selective Review. Ann Acad Med Singapore 2009; 38: 402–7. 23. Fatemi SH et al. Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex. Schizophrenia Res 2012; 134: 211–8. 24. Melka MG et al. Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis. BMC Neuroscience 2014; 15: 112.